___

• Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol 2013;23:3-9.
• Blot WJ, Devesa SS, Kneller RW, et al. Ri- sing incidence ofadenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-1289.
• Hansen S, Wiig JN, Giercksky KE, et al. Esophageal and gastriccarcinoma in Norway 1958-1992: incidence time trend variability according to morphological subtypes and organ subtypes.Int J Cancer 1997;71:340-344.
• Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in theincidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053.
• Hasegawa S, Yoshikawa T, Cho H, et al. Is adenocarcinoma of the esophagogastric junction different between Japan and wes- tern countries? the incidence and clinico- pathological features at a 4258 S. Ha- segawa et al. Japanese high-volume cancer center. World J Surg 2009;33:95-103.
• Ashraf N, Hoffe S, Kım R. Locally Advan- ced Gastroesophageal Junction Tumor: A Treatment Dilemma. TheOncologist 2015;20:134-142.
• Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomar- kers Prev 2006;15:872-878.
• Chow WH, Fraumeni JF Jr, Blot WJ et al.Body mass index and risk of adenocar- cinomas of the esophagus and gastric car- dia. J Natl Cancer Inst 1998;90:150-155.
• Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarci- noma. Cancer Res 1998;58:588.
• Yüksel C, Karabörk A, Ökten İ. Özofagus Kanserinde Helicobacter Pylori ve Barret Özofagus'un Rolü.Ankara Üniversitesi Tıp Fakültesi Mecmuası 2009;62:79-82.
• Siewert JR, Stein HJ. Classification of ade- nocarcinoma of the oesophagogastric junction. Br J Surg 1998;85:1457-1459.
• Siewert JR, Feith M, Stein H. Surgical app- roach to gastroesophageal junction can- cers. In Sugarbaker D, Bueno R, Krasna MJ, ed. Adult Chest Surgery, 1st ed. New York City: McGraw-Hill 2009;109-116.
• Rice TW, Blacstone EH, Rusch VW. A cancer staging primer: esophagus and esophagogastric junction. J Thorac Cardi- ovasc Surg 2010;139:527-529.
• Schröder W, Mönig SP, Baldus SE, et al: Frequency of nodal metastasesto the up- per mediastinum in Barrett's cancer. Ann Surg Oncol 2002;9:807-811.
• Parry K, Haverkamp L, Bruijnen RCG, et al. Surgical Treatment of Adenocarcino- mas of the Gastro-esophagealJunction. Ann Surg Oncol 2015;22:597-603.
• Kakeji Y, Yamamoto M, Ito S, et al. Lymph nodemetastasis from cancer of the esophagogastric junction, and determina- tion of the appropriate nodal dissection. Surg Today 2012;42:351-358.
• Nunobe S, Ohyama S, Sonoo H, et al: Be- nefit of mediastinal and paraaorticlymph- node dissection for advanced gastric can- cer with esophageal invasion. J Surg Oncol 2008;97:392-395.
• Mine S, Sano T, Hiki N, et al. Thoracic lymph node involvement in adenocarci- noma of the esophagogastric junction and lower esophageal squamous cell carci- noma relative to the location of the proximal end of the tumor. Ann Surg On- col 2014;21:1596-1601.
• Amenabar A, Hoppo T, Jobe BA. Surgical Management of Gastroesophageal Junc- tion Tumors. Semin Radiat Oncol 2013;23:16-23.
• Xiao WG, Ma K, Peng L, et al. Characte- risticsof lymphatic metastasis and surgical approach of adenocarcinoma of the esop- hagogastric junction. Zhonghua Wei Chang Wai Ke Za Zhi 2012;15:897-900.
• Hosokawa Y, Kinoshita T, Konishi M, et al.Clinicopathological features and prog- nostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann Surg On- col 2012;19:677-683.
• Fu SJ, Fang WT, Mao T, et al. Comparison ofoutcomes after surgery between adeno- carcinoma of the esophagogastric junction and lower thoracic esophagealsquamous cell cancer. Zhonghua Wei Chang Wai Ke Za Zhi 2012;15:893-896.
• Hasegawa S, Yoshikawa T, Rino Y, et al. Priority of Lymph Node Dissection for Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction. Ann Surg Oncol 2013;20:4252-4259.
• Kurokawa Y, Sasako M, Doki Y. Treat- ment Approaches to Esophagogastric Junction Tumors. Dig Surg 2013;30:169- 173.
• Okholm C, Svendsen LB, Achiam MP. Status and prognosis of lymph node me- tastasis in patients with cardia cancer - A systematic review. Surgical Oncology 2014;23:140-146.
• Yamashita H, Katai H, Morita S, et al. Op- timal Extent of Lymph Node Dissection for Siewert Type II Esophagogastric Junc- tion Carcinoma. Annals of Surgery 2011;254:2
• Goto H, Tokunaga M, Miki Y, et al. The optimal extent of lymph node dissection for adenocarcinoma of the esophagogast- ric junction differs between Siewert type IIand Siewert type III patients. Gastric Cancer 2015;18:375-381.
• Pedrazzani C, de Manzoni G, Marrelli D, et al. Lymph node involvement in advan- ced gastroesophageal junction adenocarci- noma. J Thorac Cardiovasc Surg 2007;134:378-385.
• Zhang YF, Shi J, Yu HP, et al. Factors pre- dicting survival in patients with proximal gastric carcinoma involving the esophagus. World J Gastroenterol 2012;18:3602-3609.
• Peyre CG, Hagen JA, DeMeester SR, et al. The number of lymph nodesremoved pre- dicts survival in esophageal cancer: An in- ternational study on the impact of extent of surgical resection. Ann Surg 2008;248:549-556.
• Kurokawa Y, Hiki N, Yoshikawa T, et al. Me- diastinal lymph node metastasis and recur- rence in adenocarcinoma of theesophago- gastric junction. Surgery 2015;157:551-555.
• Lerut T, Nafteux P, Moons J, et al. Three- field lymphadenectomy forcarcinoma of the esophagus and gastroesophageal junc- tion in 174 R0 resections: Impact on sta- ging, disease-free survival, and outcome: A plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004;240:962-972.
• Maeta M, Yamashiro H, Saito H, et al. A prospective pilot study ofextended (D3) and superextended para-aortic lymphade- nectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrec- tomy. Surgery 1999;125:325-331.
• Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-nodedissection for gastric cancer. N Engl J Med 1999;340: 908-914.
• Sasako M, McCulloch P, Kinoshita T, et al. New method to evaluate the therapeu- tic value of lymph node dissection for gastric cancer. Br J Surg 1995;82:346-351.
• Matsuda T, Takeuchi H, Tsuwano S, et al. Optimal surgicalmanagement for esopha- gogastric junction carcinoma. Gen Thorac Cardiovasc Surg 2014;62:560-566
• Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomyalone or with para-aor- tic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-462.
• Mine S, Sano T, Hiki N, et al. Lymphade- nectomy around the left renal vein in Siewert type II adenocarcinoma of the oesophagogastric junction. British Journal of Surgery 2013;100:261-266.
• Rizk N, Venkatraman E, Park B, et al. The prognostic importance of the number of involved lymph nodes in esophageal can- cer: implications for revisions of the Ame- rican Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2006; 132:1374-1381.
• Goto H, Tokunaga M, Sugisawa N, et al. Value of splenectomy in patients with Siewert type II adenocarcinoma of the esophagogastric junction. Gastric Cancer 2013;16:590-595.
• Maruyama K, Sasako M, Kinoshita T, et al. Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg 1995;19:532-536.
• Ajani JA, D'Amico TA, Almhanna K, et al. Esophageal and Esophagogastric Junc- tion Cancers, Version 1.2015. JNCCN-Jo- urnal of the National Comprehensive Cancer Network, Volume 13 Number 2, February 2015.
• Davies AR, Gossage JA, Zylstra J, et al. Tumor Stage After Neoadjuvant Chemot- herapy Determines Survival After Surgery for Adenocarcinoma of theEsophagus and Esophagogastric Junction. J Clin Oncol 2014;32:2983-2990.
• Imai K, Kakushima N, Tanaka M, et al. Validation of the application of the Japa- nese curative criteria for superficial adeno- carcinoma at the esophagogastric junction treated by endoscopic submucosal dissec- tion: a long-term analysis. SurgEndosc 2013;27:2436-2445.
• Siewert JR, Stein HJ, Feith M. Adenocar- cinoma of the esophago-gastricjunction. Scand J Surg 2006;95:260-269.
• Siewert JR, Feith M, Werner M, et al. Ade- nocarcinoma of the esophagogastric junc- tion: Results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000;232:353-361.
• Gertler R, Stein HJ, Langer R, et al. Long- term outcome of 2920 patients with can- cers of the esophagus and esophagogastric junction: Evaluation of the New Union Internationale Contre le Cancer/Ameri- can Joint Cancer Committee staging sys- tem. Ann Surg 2011;253:689-698.
• von Rahden BH, Stein HJ, Siewert JR: Sur- gical management of esophagogastric junction tumors. World J Gastroenterol 2006;12:6608-6613.
• Haverkamp L, Ruurda JP, van Leeuwen MS, et al. Systematic review of the surgical strategies of adenocarcinomas of the gast- roesophageal junction. Surgical Oncology 2014;23:222-228.
• Hulscher JBF, van Sandıck JW, de Boer AG, et al. Extended transthoracic resec- tion compared with limited transhiatal re- section for adenocarcinoma of the esop- hagus. N Engl J Med 2002;347:1662-1669.
• Feith M, Stein HJ, Siewert JR. Adenocar- cinoma of the esophagogastric junction: Surgical therapy based on 1602 consecu- tive resected patients.Surg Oncol Clin N Am 2006;15:751-764.
• Omloo JM, Lagarde SM, Hulscher JB, et al: Extended transthoracic resection com- pared with limited transhiatal resection for adenocarcinoma of the mid/distal esopha- gus: Five-year survival of a randomized cli- nical trial. Ann Surg 2007;246:992-1000.
• Mine S, Kurokawa Y, Takeuchi H, et al. Distribution of involved abdominal lymph nodes is correlated with the distance from the esophagogastric junction to the distal end of the tumor in Siewert type II tu- mors. EJSO 2015;41:1348-1353.
• Stein HJ, Feith M, Siewert JR: Individuali- zed surgical strategies for cancer of the esophagogastric junction. Ann Chir Gyna- ecol 2000;89:191-198.
• Fuchs H, Hölscher AH, Leers J, et al. Long-term quality of life after surgery for adenocarcinoma of the esophagogastric junction: extended gastrectomy or transt- horacic esophagectomy? Gastric Cancer 2016;19:312-317.
• Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdo- minal-transhiatal approach for gastric can- cer of the cardia or subcardia: a randomi- zed controlled trial. Lancet Oncol 2006;7:644-651.
• Curtis NJ, Noble F, Baıley IS, et al. The Relevance of the Siewert Classification in the Era of Multimodal Therapy for Ade- nocarcinoma of the Gastro-Oesophageal Junction. Journal of Surgical Oncology 2014;109:202-207.
• Liu K, Zhang W, Chen X, et al. Compari- son on Clinicopathological Features and Prognosis Between Esophagogastric Junc- tional Adenocarcinoma (Siewert II/III Types) and Distal Gastric Adenocarci- noma: Retrospective Cohort Study, a Single Institution, High Volume Expe- rience in China. Medicine. 2015;94: e1386.
• Kocaman G, Enön S. Ivor-Lewıs Özofa- jektomi. Erişim tarihi: 26.05.2016, http:// www.toraks.org.tr/Down- load.aspx?book=1474
• Mine S, Sano T, Hiki N, et al. Proximal margin length with transhiatal gastrectomy for Siewert type II and III adenocarcino- mas of the oesophagogastric junction. Bri- tish Journal of Surgery2013;100:1050- 1054.
• Xiao JW, Liu ZL, Ye PC, et al. Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconst- ruction after gastrectomy for Siewert types IIand IIIadenocarcinoma of the esopha- gogastric junction. World J Gastroente- rol2015;21:9999-10007.
• Pech O, Behrens A, May A, et al: Long- term results and risk factor analysis for re- currence after curative endoscopic therapy in 349 patients with high-grade intraepit- helial neoplasia and mucosal adenocarci- noma in Barrett's oesophagus. Gut 2008;57:1200-1206.